Literature DB >> 10691863

Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells.

R Fenski1, K Flesch, S Serve, M Mizuki, E Oelmann, K Kratz-Albers, J Kienast, R Leo, S Schwartz, W E Berdel, H Serve.   

Abstract

The receptor tyrosine kinase Flt3 is expressed on leukaemic blasts of most cases with acute myeloid leukaemia (AML). In order to evaluate the presence and significance of constitutive activation of Flt3 for leukaemogenesis, we (1) analysed the expression and activation status of the receptor in AML blasts; and (2) evaluated the functional consequences of constitutively active Flt3 in a myeloid progenitor cell line. Immunoprecipitation studies revealed Flt3 expression in a high proportion of AML cases (27/32) with ligand-dependent Flt3 autophosphorylation in 18, constitutive autophosphorylation in three and no autophosphorylation in six cases. Only one out of three samples with constitutively active Flt3 but 3/18 samples with ligand-dependent autophosphorylated Flt3 contained the recently described internal tandem repeat (ITR) mutations. To test the significance of Flt3 activation in myeloid cell function, we also characterized the biochemical and biological effects of the activating mutation D838V of Flt3 (FLt3D838V) on the factor-dependent myeloid progenitor cell line 32Dcl3: cells transfected with wild-type Flt3 (32D/Flt3) grew FLt3 ligand (FL) dependent, and the receptor was ligand dependently autophosphorylated. In contrast, the receptor was constitutively autophosphorylated in 32D/Flt3D838V cells, which grew independently of FL. We conclude that, in some AML samples, Flt3 is constitutively activated and that this does not correlate with ITR mutations in the juxtamembrane domain. Furthermore, constitutively active Flt3 confers factor independence to the myeloid progenitor cell line 32D. It remains to be determined whether activation of Flt3 is leukaemogenic in vivo and whether strategies aimed at inhibition of Flt3 activation could inhibit leukaemogenesis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10691863     DOI: 10.1046/j.1365-2141.2000.01831.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  27 in total

Review 1.  Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation.

Authors:  Hitoshi Kiyoi; Tomoki Naoe
Journal:  Int J Hematol       Date:  2006-05       Impact factor: 2.490

2.  High-throughput proteomic profiling reveals mechanisms of action of AMG925, a dual FLT3-CDK4/6 kinase inhibitor targeting AML and AML stem/progenitor cells.

Authors:  Zhihong Zeng; Charlie Ly; Naval Daver; Jorge Cortes; Hagop M Kantarjian; Michael Andreeff; Marina Konopleva
Journal:  Ann Hematol       Date:  2021-03-31       Impact factor: 3.673

3.  Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia.

Authors:  Derek L Stirewalt; Kenneth J Kopecky; Soheil Meshinchi; Julia H Engel; Era L Pogosova-Agadjanyan; Jeremy Linsley; Marilyn L Slovak; Cheryl L Willman; Jerald P Radich
Journal:  Blood       Date:  2005-12-20       Impact factor: 22.113

Review 4.  Molecular prognostic factors in cytogenetically normal acute myeloid leukemia.

Authors:  Alison Walker; Guido Marcucci
Journal:  Expert Rev Hematol       Date:  2012-10       Impact factor: 2.929

Review 5.  Regain control of p53: Targeting leukemia stem cells by isoform-specific HDAC inhibition.

Authors:  Ya-Huei Kuo; Jing Qi; Guerry J Cook
Journal:  Exp Hematol       Date:  2016-02-26       Impact factor: 3.084

6.  Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade.

Authors:  Talha Badar; Hagop M Kantarjian; Graciela M Nogueras-Gonzalez; Gautam Borthakur; Guillermo Garcia Manero; Michael Andreeff; Marina Konopleva; Tapan M Kadia; Naval Daver; William G Wierda; Raja Luthra; Keyur Patel; Betul Oran; Richard Champlin; Farhad Ravandi; Jorge E Cortes
Journal:  Am J Hematol       Date:  2015-09-10       Impact factor: 10.047

7.  Clinical implications of FLT3 mutations in pediatric AML.

Authors:  Soheil Meshinchi; Todd A Alonzo; Derek L Stirewalt; Michel Zwaan; Martin Zimmerman; Dirk Reinhardt; Gertjan J L Kaspers; Nyla A Heerema; Robert Gerbing; Beverly J Lange; Jerald P Radich
Journal:  Blood       Date:  2006-08-15       Impact factor: 22.113

8.  Computer aided drug discovery of highly ligand efficient, low molecular weight imidazopyridine analogs as FLT3 inhibitors.

Authors:  Brendan Frett; Nick McConnell; Catherine C Smith; Yuanxiang Wang; Neil P Shah; Hong-yu Li
Journal:  Eur J Med Chem       Date:  2015-02-28       Impact factor: 6.514

Review 9.  Potential role of sorafenib in the treatment of acute myeloid leukemia.

Authors:  Shahram Mori; Jorge Cortes; Hagop Kantarjian; Weiguo Zhang; Michael Andreef; Farhad Ravandi
Journal:  Leuk Lymphoma       Date:  2008-12

10.  Detection of FLT3 oncogene mutations in acute myeloid leukemia using conformation sensitive gel electrophoresis.

Authors:  Mamdooh Gari; Adel Abuzenadah; Adeel Chaudhary; Mohammed Al-Qahtani; Huda Banni; Waseem Ahmad; Fatin Al-Sayes; Sahira Lary; Ghazi Damanhouri
Journal:  Int J Mol Sci       Date:  2008-11-11       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.